{"blog": [], "keywords": [{"value": "Private Equity", "name": "subject", "rank": "1", "is_major": "N"}, {"value": "Mergers, Acquisitions and Divestitures", "name": "subject", "rank": "2", "is_major": "N"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "3", "is_major": "N"}, {"value": "Ethics and Official Misconduct", "name": "subject", "rank": "4", "is_major": "N"}, {"value": "Shkreli, Martin (1983- )", "name": "persons", "rank": "5", "is_major": "N"}, {"value": "Apollo Global Management", "name": "organizations", "rank": "6", "is_major": "N"}, {"value": "LyondellBasell", "name": "organizations", "rank": "7", "is_major": "N"}, {"value": "Securities and Exchange Commission", "name": "organizations", "rank": "8", "is_major": "N"}, {"value": "Turing Pharmaceuticals AG", "name": "organizations", "rank": "9", "is_major": "N"}], "web_url": "http://www.nytimes.com/2016/08/24/business/dealbook/apollo-sec-turing-lawsuit-shkreli.html", "document_type": "article", "byline": {"person": [{"lastname": "TSANG", "firstname": "Amie", "role": "reported", "organization": "", "rank": 1}], "original": "By AMIE TSANG"}, "type_of_material": "News", "multimedia": [{"url": "images/2016/08/24/business/24db-newsletter/24db-newsletter-thumbWide.jpg", "legacy": {"wide": "images/2016/08/24/business/24db-newsletter/24db-newsletter-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "subtype": "wide", "type": "image", "width": 190, "height": 126}, {"url": "images/2016/08/24/business/24db-newsletter/24db-newsletter-articleLarge.jpg", "legacy": {"xlarge": "images/2016/08/24/business/24db-newsletter/24db-newsletter-articleLarge.jpg", "xlargeheight": "400", "xlargewidth": "600"}, "subtype": "xlarge", "type": "image", "width": 600, "height": 400}, {"url": "images/2016/08/24/business/24db-newsletter/24db-newsletter-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/08/24/business/24db-newsletter/24db-newsletter-thumbStandard.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "subtype": "thumbnail", "type": "image", "width": 75, "height": 75}], "section_name": "Business Day", "word_count": "541", "source": "The New York Times", "subsection_name": "DealBook", "lead_paragraph": "A private equity firm is fined for misleading investors, a once-promising relationship goes sour, and a controversial pharmaceuticals company is back in the headlines.", "pub_date": "2016-08-24T04:00:00+0000", "news_desk": "Business", "headline": {"main": "Morning Agenda: Fining Apollo, When Deals Go Sour, and Controversy at Turing"}, "print_page": null, "snippet": "A private equity firm is fined for misleading investors, a once-promising relationship goes sour, and a controversial pharmaceuticals company is back in the headlines....", "_id": "57bd70d595d0e021d79824af", "slideshow_credits": null, "abstract": null}